$EXEL Headlines Apple, Tesla hit intraday records;

New Post Public Reply Private Reply Replies (0) Message Board

Oct 4, 2014 at 1:46 PM

$EXEL Headlines

Apple, Tesla hit intraday records; Possible breach at Home Depot 3:15 p.m. Sept. 2, 2014 - Angela Johnson
Exelixis shares plunge 55% after disappointing trial results 9:40 a.m. Sept. 2, 2014 - Tomi Kilgore
Biotechs still sliding, but Wall Street says don't hit panic button just yet 2:43 p.m. March 26, 2014 - Russ Britt
HMA’s pre-emptive strike against ‘60 Minutes’ 5:44 p.m. Nov. 30, 2012 - Russ Britt
Chipotle vs. Taco Bell: testing Einhorn's thesis 6:37 a.m. Oct. 4, 2012 - The Trading Deck
Exelixis prices stock offering at 0.7% discount 12:21 p.m. Aug. 9, 2012 - MarketWatch.com
Exelixis slides 12% on stock, debt offering 3:39 p.m. Aug. 6, 2012 - Val Brickates Kennedy
FDA to speed Exelixis thyroid-cancer-drug review 6:35 a.m. July 30, 2012 - MarketWatch.com
Stocks to watch Thursday: GM, Agilent, NetApp 7:51 a.m. Feb. 16, 2012 - MarketWatch
Exelixis licenses cancer-drug R&D to Merck & Co. 8:26 a.m. Dec. 21, 2011 - MarketWatch.com
Loathe that investment theme? Perfect! 1:03 p.m. Nov. 8, 2011 - The Trading Deck
Exelixis plunges on drug study woes 12:05 p.m. Nov. 1, 2011 - Val Brickates Kennedy
Stocks to watch Tuesday: Exelixis, DirecTV, Leap 6:46 a.m. Nov. 1, 2011 - MarketWatch
Exelixis slides, Allstate up in after-hours trade 6:48 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis shares fall without FDA study commentary 6:05 p.m. Oct. 31, 2011 - Wallace Witkowski
Exelixis shares resume trading, drop 35% 5:44 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis rallies 21% on drug study 11:46 a.m. Oct. 24, 2011 - Val Brickates Kennedy
Icahn reports new stakes in Vector Group, El Paso 7:52 p.m. Aug. 15, 2011 - MarketWatch.com
ASCO studies shake up drug stocks 4:17 p.m. June 7, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 6:50 p.m. June 6, 2011 - Kate Gibson

Ad Comm smacks down Sonacare's HIFU device for prostate cancer 1:53 p.m. Oct. 3, 2014 - Seeking Alpha
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog 9:50 a.m. Oct. 3, 2014 - Zacks.com
Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape 9:41 a.m. Oct. 3, 2014 - Zacks.com
Update: Exelixis Announces Very Positive Results From The CoBRIM Trial - Impacts To My Bull Thesis 9:57 a.m. Sept. 29, 2014 - Seeking Alpha
Exelixis up on clinical trial results 7:38 a.m. Sept. 29, 2014 - Seeking Alpha
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. 7:41 p.m. Sept. 28, 2014 - GuruFocus.com
Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape 8:53 a.m. Sept. 18, 2014 - Zacks.com
Anika Therapeutics: A Recent Greenblatt Small Cap Biotech Pick 8:38 a.m. Sept. 16, 2014 - Seeking Alpha
Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious 8:41 a.m. Sept. 15, 2014 - Seeking Alpha
Exelixis' (EXEL) CEO Michael Morrissey Presents at Morgan Stanley Healthcare Conference (Transcript) 6:04 p.m. Sept. 9, 2014 - Seeking Alpha
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST 8:29 p.m. Sept. 6, 2014 - GuruFocus.com
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte 8:55 a.m. Sept. 5, 2014 - TheStreet.com
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog 10:40 a.m. Sept. 3, 2014 - Zacks.com
Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape 9:38 a.m. Sept. 3, 2014 - Zacks.com
Update: Exelixis COMET-1 Trial Fails: The Impact To My Bull Thesis 2:38 p.m. Sept. 2, 2014 - Seeking Alpha
Exelixis' CEO Presents at COMET-1 Results Conference (Transcript) 12:35 p.m. Sept. 2, 2014 - Seeking Alpha
Exelixis' (EXEL) CEO Mike Morrissey Hosts COMET-1 Results Conference (Transcript) 12:35 p.m. Sept. 2, 2014 - Seeking Alpha
After the Exelixis Implosion, Is There Anything Left Ahead? 10:10 a.m. Sept. 2, 2014 - 247WallSt.com
Benzinga's Top Downgrades 7:53 a.m. Sept. 2, 2014 - benzinga.com
Stifel Nicolaus Downgrades Exelixis To Hold 7:24 a.m. Sept. 2, 2014 - benzinga.com

Exelixis Announces Positive Results from Phase 3 Pivotal Trial ofCobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma 3:00 a.m. Sept. 29, 2014 - BusinessWire - BZX
Exelixis Announces Cobimetinib Phase3coBRIM Results toBePresented at ESMO 2014 Congress 1:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 8:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Exelixis to Present at theMorgan Stanley Global Healthcare Conference on Tuesday, September 9 4:05 p.m. Sept. 8, 2014 - BusinessWire - BZX
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trialof Cabozantinib in Men with MetastaticCastration-ResistantProstate Cancer 6:00 p.m. Sept. 1, 2014 - BusinessWire - BZX
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Exelixis Announces Second Quarter 2014 Financial Results 4:14 p.m. July 31, 2014 - BusinessWire - BZX
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Biotech Companies Release Quarterly Financials and Announce Earnings Release Dates - Research Reports on Illumina, Alexion, Questcor, Jazz Pharmaceuticals and Exelixis 8:40 a.m. July 29, 2014 - PR Newswire - PRF
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead 8:40 a.m. July 18, 2014 - PR Newswire - PRF
Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc. 3:05 p.m. July 17, 2014 - PR Newswire - PRF
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 4:06 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma 2:18 a.m. July 14, 2014 - BusinessWire - BZX
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 4:15 p.m. June 3, 2014 - BusinessWire - BZX
Technical Coverage on Health Care Sector Equities -- Research on Arena Pharma, Exelixis, Dendreon, and Seattle Genetics 7:40 a.m. May 30, 2014 - PR Newswire - PRF
Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib atEADOCongress2014 1:01 a.m. May 7, 2014 - BusinessWire - BZX
Exelixis to Present at Two Investor Conferences in May 4:20 p.m. May 6, 2014 - BusinessWire - BZX
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte 9:57 a.m. May 6, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FDI Launches 'Generation Smile' for Global Oral Health

A New Kind of Movement Imagine a campaign not bound by age or geography but united by a shared mission. Generation Smile, freshly launched by the FDI World Dental Federation in Prague, is just that kind of uprising. This initiative redefines existing approaches to oral health, pushing beyond the boundaries of mere dental care to emphasize the integral role oral health...

UST Grabs Italdesign: Driving Future Mobility with AI

UST's Strategic Move Into Automotive's Future Wake up and smell the coffee, because UST is shaking up the automotive scene. They've just pulled off a major play by grabbing a majority stake in Italdesign. If that doesn't scream the next leap forward for the auto world, I don't know what does. UST isn't just buying a company; it's marrying Italdesign's legendary design...

Multiconsult-Rejlers Merger Revs Up Nordic Market Power

A New Powerhouse in the Nordic Consultancy Space September 7, 2026, will likely be etched into the annals of stock market moves, marking the day two titans, Multiconsult and Rejlers, decided to tie the knot. This isn't your average merger. We're talking about a calculated Pan-Nordic push that's been building, and now, well, it's paying off with a potential powerhouse of...

WEPSEA 2026 Propels Southeast Asia's Packaging Leap

Revolution in Packaging: Southeast Asia Steps Up Get ready for a wake-up call in the world of packaging, folks; the Southeast Asian market is taking a sharp turn toward sustainability and technological advancement, as highlighted by WEPSEA 2026's recent wrap-up in Shanghai. Far from a mere exhibition, this gathering served as the crucible for change, where old-school...

TECNO CAMON Slim 5G: Where Art Meets Tech

Unveiling the TECNO CAMON Slim 5G Okay, so imagine a tech brand saying, 'Why not make a phone that’s as much an art piece as it is a gadget?' TECNO just pulled this off with their latest CAMON Slim 5G. The thing's a sleek marvel measuring in at just 6.39mm. Seems like they took a fat-free diet approach to phone design, and not on the digital calories either. A Slim Body...

EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

China's Manufacturing: Squeeze or Opportunity?

Analyzing China's Impact on Global Markets Think of China's manufacturing clout and you're likely to picture booming factories, relentless steel, and smoke-churning industries reshaping the global chessboard. But here's the kicker: are they swallowing up room for others, or paving the way for their growth? It’s this debate that took the spotlight at the Asia-Pacific...

Harbour BioMed Joins Stock Connect, Boosts Investor Access

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...